Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Vaccines01:30

Cancer Vaccines

932
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
932
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and validation of a reaching-task system for quantifying wrist extension recovery after radial nerve repair in nonhuman primates.

Journal of neuroscience methods·2026
Same author

High-resolution photogrammetry reveals links between reef structural complexity, fish communities, and human influence in a remote Pacific atoll.

The Science of the total environment·2026
Same author

Transmembrane orientation and extracellular juxtamembrane residues of GP130 are critical for signal transduction.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Hidden architecture of resistance: The extracellular matrix in melanoma's immune landscape.

Seminars in cancer biology·2026
Same author

Pseudomyxoma peritonei and the microbiome: Emerging observations and unanswered questions.

Trends in cancer·2026
Same author

Whole genome sequencing in oesophageal adenocarcinoma unmasks potential precision therapies.

BMC cancer·2026

Related Experiment Video

Updated: Jan 9, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.8K

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.

Joshua K M Wong1, Pui Yeng Lam1, Elaina Coleborn1

  • 1Frazer Institute, The University of Queensland, Woolloongabba, QLD 4102, Australia.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|December 3, 2025
PubMed
Summary

Researchers developed novel therapies targeting Receptor tyrosine kinase-like orphan receptor 1 (ROR1) for triple-negative breast cancer (TNBC). Combining ROR1-targeting with TGF-β inhibition enhanced anti-cancer efficacy and persistence.

Keywords:
ADCCCAR NK cellsCRISPR/Cas9Frizzled-Kringle domainTGFBR2 knockoutantibody drug conjugatenatural killer cellsphage displayscFvtriple negative breast cancer

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.2K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K

Related Experiment Videos

Last Updated: Jan 9, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.8K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.2K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.4K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is highly expressed in aggressive triple-negative breast cancer (TNBC).
  • Current ROR1-targeting therapies, like CAR T cells, show promise but face challenges with efficacy and toxicity.
  • Natural Killer (NK) cell-based immunotherapies offer a potentially safer alternative for cancer treatment.

Purpose of the Study:

  • To develop novel ROR1-targeting immunotherapies for TNBC.
  • To evaluate the efficacy of ROR1-targeting chimeric monoclonal antibodies and CAR NK cells against TNBC.
  • To investigate the synergistic effect of TGF-β inhibition on ROR1-targeting therapies.

Main Methods:

  • Development of a phage-derived single-chain fragment variable (scFv) targeting ROR1.
  • Generation of scFv-derived chimeric monoclonal antibodies and ROR1-specific CAR NK cells.
  • Assessment of anti-cancer efficacy against TNBC cells and evaluation of TGF-β inhibition strategies.

Main Results:

  • The developed scFv-based antibodies and CAR NK cells demonstrated anti-cancer efficacy against TNBC cells.
  • ROR1-targeting therapies showed improved persistence and efficacy when combined with TGF-β inhibition.
  • TGF-β inhibition was achieved using small-molecule inhibitors or CRISPR-Cas9-edited NK cells.

Conclusions:

  • Novel ROR1-targeting immunotherapies, including CAR NK cells, are effective against TNBC.
  • Combining ROR1-targeting strategies with TGF-β inhibition significantly enhances therapeutic outcomes.
  • These findings support the development of advanced ROR1-based immunotherapies for TNBC treatment.